Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

Cancer

Volumn 121, Issue 4, 2015, Pages 498-501

  Lübbert, Michael ^a   Kuendgen, Andrea ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; PANOBINOSTAT; PRACINOSTAT; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EDITORIAL; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HEMATOLOGIC DISEASE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; ENZYMOLOGY; LEUKEMIA, MYELOID, ACUTE; METHODOLOGY; MYELODYSPLASTIC SYNDROMES; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA MODIFICATION METHYLASES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; RESEARCH DESIGN; TREATMENT FAILURE; VALPROIC ACID;

EID: 84922553345     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29083     Document Type: Editorial

References (21)

1. Jahangeer S, Elliott RM, Henneberry RC. β-Adrenergic receptor induction in HeLa cells: Synergistic effect of 5-zzacytidine and butyrate. Biochem Biophys Res Commun. 1982;108:1434-1440.
2. Daskalakis M, Joeckel TE, Lübbert M, Kuendgen A. Treatment of hematologic malignancies with DNA hypomethylating agents. In: Lübbert M, Jones PA, eds. Epigenetic Therapy of Cancer. Heidelberg, Germany: Springer; 2014:145-170.
3. Brown R, Steinmann J, Graham J, Glasspool R. Epigenetic therapies in solid tumours: from preclinical models to clinical trial results. In: Lübbert M, Jones PA, eds. Epigenetic Therapy of Cancer. Heidelberg, Germany: Springer; 2014:299-317.
4. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103-107.
5. Fenaux P, Mufti G, Hellström-Lindberg E, et al. Efficacy of azacitidine (AZA) compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10:113-132.
6. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
7. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-2677.
8. Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet. 2010;1:117-136.
9. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
10. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84(suppl 1):61-66.
11. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-20'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
12. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302-2308.
13. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2010;1:34-42.
14. Kuendgen A, Bug G, Ottmann OG, et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenet. 2011;2:389-399.
15. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res. 2009;15:5002-5007.
16. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908-1918.
17. Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121:556-561.
18. Prebet T, Sun Z, Figueroa M, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. J Clin Oncol. 2014;32:1242-1248.
19. Treppendahl MB, Kristensen LS, Gronbaek K. Predicting response to epigenetic therapy. J Clin Invest. 2014;124:47-55.
20. Pandiyan K, You JS, Yang X, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013;41:3973-3985.
21. Ferrara F, Musto P. What is better for older patients with acute myeloid leukemia? J Clin Oncol. 2013;31:820-821.